Xoma Corp. (NASDAQ:XOMA) has been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the firm. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $2.50.

Several brokerages have weighed in on XOMA. Zacks Investment Research lowered shares of Xoma Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 26th. Cowen and Company reaffirmed a “market perform” rating on shares of Xoma Corp. in a research note on Monday, September 19th. Wedbush reaffirmed an “outperform” rating and set a $3.00 target price (up previously from $1.42) on shares of Xoma Corp. in a research note on Friday, September 16th. Finally, Jefferies Group reissued a “hold” rating on shares of Xoma Corp. in a research note on Friday, August 5th.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Spark Investment Management LLC raised its position in Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares during the last quarter. Bellevue Group AG acquired a new position in Xoma Corp. during the first quarter valued at approximately $174,000. Paloma Partners Management Co acquired a new position in Xoma Corp. during the second quarter valued at approximately $185,000. Wedbush Securities Inc. raised its position in Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock valued at $223,000 after buying an additional 15,827 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Xoma Corp. during the first quarter valued at approximately $374,000. 17.13% of the stock is owned by institutional investors and hedge funds.

Xoma Corp. (NASDAQ:XOMA) traded down 3.3636% during mid-day trading on Tuesday, reaching $0.4252. 363,196 shares of the company’s stock traded hands. The stock’s 50 day moving average is $0.55 and its 200-day moving average is $0.64. The stock has a market capitalization of $51.27 million, a PE ratio of 38.6545 and a beta of 2.87. Xoma Corp. has a 52 week low of $0.42 and a 52 week high of $2.03.

Xoma Corp. (NASDAQ:XOMA) last announced its earnings results on Wednesday, August 3rd. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.01. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.84 million. During the same period in the previous year, the business posted ($0.20) earnings per share. On average, equities analysts anticipate that Xoma Corp. will post ($0.47) EPS for the current year.

Xoma Corp. Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

5 Day Chart for NASDAQ:XOMA

Receive News & Stock Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related stocks with our FREE daily email newsletter.